Loading...
Loading...
- Inspire Medical Systems Inc INSP expects Q4 FY21 revenue of $78.0 million - $78.4 million, up approximately 70% Y/Y and surpassing the consensus estimate of $65.84 million.
- For FY21, the Company sees sales of $233.0 million - $233.4 million, an approximately 102% increase over FY20.
- Inspire activated 81 new centers in the U.S. in Q4 FY21, bringing the total to 684 U.S. medical centers implanting Inspire therapy.
- The Company also received FDA approval for the Inspire Bluetooth-enabled patient remote control during the quarter.
- The Company will report its full financial results for 2021 on February 8, 2022.
- Price Action: INSP shares closed at $232.65 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in